256 related articles for article (PubMed ID: 35143256)
1. Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination.
Kaku CI; Champney ER; Normark J; Garcia M; Johnson CE; Ahlm C; Christ W; Sakharkar M; Ackerman ME; Klingström J; Forsell MNE; Walker LM
Science; 2022 Mar; 375(6584):1041-1047. PubMed ID: 35143256
[TBL] [Abstract][Full Text] [Related]
2. Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination.
Younes S; Nicolai E; Pieri M; Bernardini S; Daas HI; Al-Sadeq DW; Younes N; Shurrab FM; Nizamuddin PB; Humaira F; Al-Dewik N; Yassine HM; Abu-Raddad LJ; Ismail A; Nasrallah GK
Influenza Other Respir Viruses; 2024 May; 18(5):e13290. PubMed ID: 38706402
[TBL] [Abstract][Full Text] [Related]
3. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.
Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M
Front Immunol; 2022; 13():811020. PubMed ID: 35126395
[TBL] [Abstract][Full Text] [Related]
4. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination.
Pozzetto B; Legros V; Djebali S; Barateau V; Guibert N; Villard M; Peyrot L; Allatif O; Fassier JB; Massardier-Pilonchéry A; Brengel-Pesce K; Yaugel-Novoa M; Denolly S; Boson B; Bourlet T; Bal A; Valette M; Andrieu T; Lina B; ; Cosset FL; Paul S; Defrance T; Marvel J; Walzer T; Trouillet-Assant S
Nature; 2021 Dec; 600(7890):701-706. PubMed ID: 34673755
[TBL] [Abstract][Full Text] [Related]
6. Distinct T cell responsiveness to different COVID-19 vaccines and cross-reactivity to SARS-CoV-2 variants with age and CMV status.
Brummelman J; Suárez-Hernández S; de Rond L; Bogaard-van Maurik M; Molenaar P; van Wijlen E; Oomen D; Beckers L; Rots NY; van Beek J; Nicolaie MA; van Els CACM; Boer MC; Kaaijk P; Buisman AM; de Wit J
Front Immunol; 2024; 15():1392477. PubMed ID: 38774878
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Folegatti PM; Ewer KJ; Aley PK; Angus B; Becker S; Belij-Rammerstorfer S; Bellamy D; Bibi S; Bittaye M; Clutterbuck EA; Dold C; Faust SN; Finn A; Flaxman AL; Hallis B; Heath P; Jenkin D; Lazarus R; Makinson R; Minassian AM; Pollock KM; Ramasamy M; Robinson H; Snape M; Tarrant R; Voysey M; Green C; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
Lancet; 2020 Aug; 396(10249):467-478. PubMed ID: 32702298
[TBL] [Abstract][Full Text] [Related]
8. Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination.
Cho A; Muecksch F; Schaefer-Babajew D; Wang Z; Finkin S; Gaebler C; Ramos V; Cipolla M; Mendoza P; Agudelo M; Bednarski E; DaSilva J; Shimeliovich I; Dizon J; Daga M; Millard KG; Turroja M; Schmidt F; Zhang F; Tanfous TB; Jankovic M; Oliveria TY; Gazumyan A; Caskey M; Bieniasz PD; Hatziioannou T; Nussenzweig MC
Nature; 2021 Dec; 600(7889):517-522. PubMed ID: 34619745
[TBL] [Abstract][Full Text] [Related]
9. Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates.
Corbett KS; Gagne M; Wagner DA; O' Connell S; Narpala SR; Flebbe DR; Andrew SF; Davis RL; Flynn B; Johnston TS; Stringham CD; Lai L; Valentin D; Van Ry A; Flinchbaugh Z; Werner AP; Moliva JI; Sriparna M; O'Dell S; Schmidt SD; Tucker C; Choi A; Koch M; Bock KW; Minai M; Nagata BM; Alvarado GS; Henry AR; Laboune F; Schramm CA; Zhang Y; Yang ES; Wang L; Choe M; Boyoglu-Barnum S; Wei S; Lamb E; Nurmukhambetova ST; Provost SJ; Donaldson MM; Marquez J; Todd JM; Cook A; Dodson A; Pekosz A; Boritz E; Ploquin A; Doria-Rose N; Pessaint L; Andersen H; Foulds KE; Misasi J; Wu K; Carfi A; Nason MC; Mascola J; Moore IN; Edwards DK; Lewis MG; Suthar MS; Roederer M; McDermott A; Douek DC; Sullivan NJ; Graham BS; Seder RA
Science; 2021 Dec; 374(6573):1343-1353. PubMed ID: 34672695
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of Two Doses of BNT162b2 mRNA COVID-19 Vaccine with a ChAdOx1-S Booster Dose among Navy Personnel in Mexico.
Ventura-Enríquez Y; Cortina-De la Rosa E; Díaz-Padilla E; Murrieta S; Segundo-Martínez S; Fernández-Sánchez V; Vargas-De-León C
Viruses; 2024 Apr; 16(4):. PubMed ID: 38675894
[TBL] [Abstract][Full Text] [Related]
11. Anti-SARS-CoV-2 Spike Protein RBD Antibody Levels After Receiving a Second Dose of ChAdOx1 nCov-19 (AZD1222) Vaccine in Healthcare Workers: Lack of Association With Age, Sex, Obesity, and Adverse Reactions.
Lee SW; Moon JY; Lee SK; Lee H; Moon S; Chung SJ; Yeo Y; Park TS; Park DW; Kim TH; Sohn JW; Yoon HJ; Kim SH
Front Immunol; 2021; 12():779212. PubMed ID: 34899739
[TBL] [Abstract][Full Text] [Related]
12. Homologous and Heterologous Covid-19 Booster Vaccinations.
Atmar RL; Lyke KE; Deming ME; Jackson LA; Branche AR; El Sahly HM; Rostad CA; Martin JM; Johnston C; Rupp RE; Mulligan MJ; Brady RC; Frenck RW; Bäcker M; Kottkamp AC; Babu TM; Rajakumar K; Edupuganti S; Dobrzynski D; Coler RN; Posavad CM; Archer JI; Crandon S; Nayak SU; Szydlo D; Zemanek JA; Dominguez Islas CP; Brown ER; Suthar MS; McElrath MJ; McDermott AB; O'Connell SE; Montefiori DC; Eaton A; Neuzil KM; Stephens DS; Roberts PC; Beigel JH;
N Engl J Med; 2022 Mar; 386(11):1046-1057. PubMed ID: 35081293
[TBL] [Abstract][Full Text] [Related]
13. An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial.
Saraf A; Gurjar R; Kaviraj S; Kulkarni A; Kumar D; Kulkarni R; Virkar R; Krishnan J; Yadav A; Baranwal E; Singh A; Raghuwanshi A; Agarwal P; Savergave L; Singh S;
Nat Med; 2024 May; 30(5):1363-1372. PubMed ID: 38637636
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Liu X; Shaw RH; Stuart ASV; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Dinesh T; England A; Faust SN; Ferreira DM; Finn A; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Lazarus R; Libri V; Long F; Mujadidi YF; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Singh N; Turner DPJ; Turner PJ; Walker LL; White R; Nguyen-Van-Tam JS; Snape MD;
Lancet; 2021 Sep; 398(10303):856-869. PubMed ID: 34370971
[TBL] [Abstract][Full Text] [Related]
15. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination.
Barros-Martins J; Hammerschmidt SI; Cossmann A; Odak I; Stankov MV; Morillas Ramos G; Dopfer-Jablonka A; Heidemann A; Ritter C; Friedrichsen M; Schultze-Florey C; Ravens I; Willenzon S; Bubke A; Ristenpart J; Janssen A; Ssebyatika G; Bernhardt G; Münch J; Hoffmann M; Pöhlmann S; Krey T; Bošnjak B; Förster R; Behrens GMN
Nat Med; 2021 Sep; 27(9):1525-1529. PubMed ID: 34262158
[TBL] [Abstract][Full Text] [Related]
16. Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination.
Sheng WH; Chang SY; Lin PH; Hsieh MJ; Chang HH; Cheng CY; Yang HC; Pan CF; Ieong SM; Chao TL; Chen JP; Cheng SH; Chang SC
J Formos Med Assoc; 2022 Apr; 121(4):766-777. PubMed ID: 35305895
[TBL] [Abstract][Full Text] [Related]
17. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
18. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Barrett JR; Belij-Rammerstorfer S; Dold C; Ewer KJ; Folegatti PM; Gilbride C; Halkerston R; Hill J; Jenkin D; Stockdale L; Verheul MK; Aley PK; Angus B; Bellamy D; Berrie E; Bibi S; Bittaye M; Carroll MW; Cavell B; Clutterbuck EA; Edwards N; Flaxman A; Fuskova M; Gorringe A; Hallis B; Kerridge S; Lawrie AM; Linder A; Liu X; Madhavan M; Makinson R; Mellors J; Minassian A; Moore M; Mujadidi Y; Plested E; Poulton I; Ramasamy MN; Robinson H; Rollier CS; Song R; Snape MD; Tarrant R; Taylor S; Thomas KM; Voysey M; Watson MEE; Wright D; Douglas AD; Green CM; Hill AVS; Lambe T; Gilbert S; Pollard AJ;
Nat Med; 2021 Feb; 27(2):279-288. PubMed ID: 33335322
[TBL] [Abstract][Full Text] [Related]
19. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.
Hillus D; Schwarz T; Tober-Lau P; Vanshylla K; Hastor H; Thibeault C; Jentzsch S; Helbig ET; Lippert LJ; Tscheak P; Schmidt ML; Riege J; Solarek A; von Kalle C; Dang-Heine C; Gruell H; Kopankiewicz P; Suttorp N; Drosten C; Bias H; Seybold J; ; Klein F; Kurth F; Corman VM; Sander LE
Lancet Respir Med; 2021 Nov; 9(11):1255-1265. PubMed ID: 34391547
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan.
Kang CM; Lee NY; Lin CH; Hsu YS; Chang YC; Chung MY; Lee YF; Tseng WP; Wu JL; Chen SY; Lu MC; Ko WC; Lee PI; Hsueh PR
J Clin Virol; 2022 Jun; 150-151():105156. PubMed ID: 35413588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
